Biocardia Inc (BCDA) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Biocardia Inc   (NASDAQ: BCDA)


Biocardia Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Biocardia Inc 's ROA in the second quarter of 2026?
Biocardia Inc recorded a cumulative net loss of $-7 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -179.27%.

However, within the Healthcare sector 842 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4523, from total ROA ranking in the first quarter of 2026 at 5234.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 144.23 % -41.89 % -6.62 % 0.74 % -27.72 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -7 -8 -8 -9 -9
Return On Assets (TTM) -179.27 % -232.75 % -225.49 % -230.22 % -237.79 %
BCDA's Total Ranking # 4523 # 5234 # 4644 # 4720 # 4772
Total Assets (TTM) in million 5 2 3 6 2
Seq. Total Assets Change 198.01 % -49.84 % -44.49 % 194.3 % -29.09 %
Seq. Net Income Change - - - - -

BCDA's 5 Years Annual ROA >> Back to BCDA Management Effectiveness >> Compare BCDA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 131
Sector # 843
Overall # 4418

Return On Assets Statistics
High Average Low
104.17 %
-110.29 %
-294.29 %
(Sep 30 2012)   (Jun 30 2019)



  News about Biocardia Inc Return on Assets ROA

BioCardia Inc. Making Strides in Innovative Therapies A Look at Recent Developments

In recent weeks, BioCardia Inc., a developer of cellular and cell-derived therapeutics for cardiovascular diseases, has been making significant progress in the field of innovative therapies. From receiving a United States Patent for their Morph DNA Multi-Directional Steerable Catheter Transseptal Application to collaborating on a successful Phase II Trial with CellProthera, BioCardia is paving the way for groundbreaking advancements in cardiovascular care. This article aims to outline the key facts and assess the impact of these developments on the industry.BioCardia s United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application:On July 17, 2024, BioCardia announced the issuance of a United States Patent for their Morph DNA Multi-Directional Steerable Catheter Transseptal Application. This invention holds great potential for revolutionizing cardiac catheterization procedures by allowing greater precision and control during interventions. The patent signifies a significant achievement for BioCardia, showcasing their commitment to pushing boundaries and improving patient outcomes.



Financial Statements
Biocardia Inc 's Assets $ 5 million BCDA's Balance sheet
Biocardia Inc 's Income $ -2 million Quarterly BCDA's Income Statement
BCDA's Income by Division See BCDA's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -6.62 % 22.36 % -66.94 % -38.39 % -37.4 %
Total Assets in million 3 4 3 9 15
Y / Y Net Income Change - - - - -
Net Income in million -8 -8 -12 -12 -13
Annual Return On Assets -241.08 % -217.4 % -387.38 % -131.8 % -86.09 %

BCDA's 5 Years Annual ROA >> Back to BCDA Management Effectiveness >> Compare BCDA ROA to its Competitors



More Return On Assets Ratios
BCDA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BCDA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BCDA's Competitors
Subscribers only: Roa for Biocardia Inc 's Suppliers
Subscribers only: Return On Assets for BCDA's Customers

You may also want to know
BCDA's Roi BCDA's Inventory Turnover Ratio BCDA's Growth Rates BCDA's Dividend Comparisons
BCDA's Profitability Ratios BCDA's Asset Turnover Ratio BCDA's Dividend Growth
BCDA's Roe BCDA's Valuation Ratios BCDA's Financial Strength Ratios BCDA's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-08T16:44:26+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.